Status:
COMPLETED
Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration
Lead Sponsor:
Ulucanlar Eye Training and Research Hospital
Conditions:
Age Related Macular Degeneration
Eligibility:
All Genders
55-76 years
Brief Summary
Aflibercept is the most recently developed VEGF inhibitor with a recombinant fusion protein consisting of human VEGF receptor extracellular domains from receptors 1 and 2 (VEGFR1 and VEGFR2) fused to ...
Detailed Description
Intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors have being increasingly used in the treatment of neovascular age-related macular degeneration (AMD) in ophthalmic practi...
Eligibility Criteria
Inclusion
- The inclusion criteria were angiographic and optical coherence tomographic evidence of neovascular AMD.
- \-
Exclusion
- age more than 80 years
- specific corneal conditions such as Fuchs endothelial dystrophy and other corneal endothelial dystrophies
- history of ocular surgery
- history of contact lenses use
- ocular and systemic diseases such as diabetes and connective tissue disorders that could effect the corneal endothelium
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT03313401
Start Date
January 1 2017
End Date
June 1 2017
Last Update
October 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.